Previous 10 | Next 10 |
home / stock / dskyf / dskyf news
2023-08-29 08:46:13 ET Summary Esperion reported Q2 bempedoic acid revenue of $20.3M; we expect the bempedoic acid to surpass the 2023 consensus numbers. The ongoing Daiichi litigation poses a significant weight on Esperion's stock price and financials, but at this valuation, risk...
2023-08-21 15:58:31 ET More on Eli Lilly Eli Lilly Q2: Dividends Don't Lie Eli Lilly: Q2 And 2023 Revised Guidance Impressive, But Key Is Wegovy Data Eli Lilly and Co ( LLY ) Q2 2023 Earnings Call Transcript Eli Lilly Remains A Buy With Strong Sales And P...
2023-08-01 13:32:44 ET More on Daiichi Sankyo Daiichi Sankyo Company, Limited ( OTCPK:DSKYF ) Q1 2023 Earnings Call Transcript Shionogi & Co., Ltd. ( OTCPK:SGIOF ) Q1 2023 Earnings Call Transcript Daiichi Sankyo: There Is A Lot Of Room To Grow Dai...
2023-07-31 22:12:02 ET Daiichi Sankyo Company, Limited (DSKYF) Q1 2023 Earnings Conference Call July 31, 2023, 2:00 AM ET Company Participants Kentaro Asakura - Vice President of Corporate Communications Department Koji Ogawa - Executive Officer and Chief Financial O...
2023-07-31 10:51:57 ET Daiichi Sankyo press release ( OTCPK:DSKYF ): Q1 GAAP EPS of ¥29.72. Revenue of ¥350.84B (+25.2% Y/Y). For further details see: Daiichi Sankyo GAAP EPS of ¥29.72, revenue of ¥350.84B
2023-07-13 11:15:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. Japan drove internatio...
2023-07-12 07:30:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. Japan drove internatio...
2023-05-26 03:13:14 ET Summary Daiichi Sankyo is leading the world in the development of antibody-drug conjugates, which are finally paying off in cancer after more than a decade of ups and downs. The company stands poised to continue to stretch its arms in the space and reap sign...
2023-05-01 15:40:06 ET Daiichi Sankyo Company, Limited (DSKYF) Q4 2022 Results Conference Call April 27, 2023 04:30 AM ET Company Participants Hiroyuki Okuzawa - Head, Corporate Planning and Management Division, CFO Ken Takeshita - Global Head of Research and Develop...
2023-04-27 10:16:50 ET Daiichi Sankyo Co. ( OTCPK:DSKYF ): FY GAAP EPS of ¥56.91. Revenue of ¥1.28T. For further details see: Daiichi Sankyo Co. GAAP EPS of ¥56.91, revenue of ¥1.28T
News, Short Squeeze, Breakout and More Instantly...
Daiichi Sankyo Co Ltd Company Name:
DSKYF Stock Symbol:
OTCMKTS Market:
Publication highlights Europe -specific one-year follow-up findings for atrial fibrillation (AF) patients in routine clinical practice, in which, rates of stroke, systemic embolism, and major bleeding are considered by the authors to be low in edoxaban treated patients [1] Findings...
· Results published in the European Heart Journal – Cardiovascular Pharmacotherapy , showed rates of thromboembolism similar to those observed in the ENGAGE AF-TIMI 48 clinical trial [1] · Study reports LIXIANA outcomes from one of the largest observational ...
- ENTRUST-AF PCI study achieved the primary safety endpoint of non-inferiority in bleeding for edoxaban-based dual therapy compared with VKA-based triple antithrombotic therapy (using a risk-based duration of ASA for at least one month) in AF patients following stent placement - ...